Celularity Inc. stocks have been trading down by -29.05 percent after negative sentiment over its latest financing and dilution concerns.
What Traders Need To Know
- Celularity received a Nasdaq notice for failing to file its Q1 and Q2 2026 Form 10-Qs, putting it out of compliance with Nasdaq Listing Rule 5250(c)(1).
- The company must submit a plan to Nasdaq to regain compliance by 2026/09/04.
- Any compliance exception granted by Nasdaq would extend only until 2026/11/16.
- Despite the non-compliance notice, Celularity’s shares remain listed and trading on Nasdaq while it works to complete the delayed filings.
Weekly Update Aug 24 – Aug 28, 2026: On Saturday, August 29, 2026 Celularity Inc. stock [NASDAQ: CELU] is trending down by -29.05%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – negative
Celularity’s fundamentals are extremely weak: revenue of ~$26.5M with gross margin of 24% is overwhelmed by massive operating losses (EBIT margin below -300%) and negative free cash flow of ~$5.1M in Q4 2025 alone. Equity is deeply negative (book value per share -$0.69, stockholders’ equity -$38M) with a current ratio of 0.2 and quick ratio 0.1, highlighting acute liquidity risk. Negative ROA near -50–75% and heavy SG&A burden signal an unsustainable standalone model.
Technically, CELU has shifted from a low‑volume sub‑$1 base (0.75–0.90) into a sharp, news‑driven spike to $2.01 followed by an immediate fade to $1.49, indicating a short‑term blow‑off and profit‑taking. The dominant trend on the weekly tape is still down, with the recent surge likely a short squeeze or speculative event. The actionable level is $1.40–1.45 support; a decisive break below favors short bias, while failed pushes above $2.00 are sell/short opportunities.
More Breaking News
- BTG Stock Pulls Back As Charts Flash Key Support
- PATH Stock Slips As BofA Slashes UiPath Price Target
- SPCX Slides As Headline Risk And Competition Hammer Sentiment
- TNMG Stock Pullback Puts TNL Mediagene On Watch
The Nasdaq non‑compliance notice for delinquent 10‑Qs materially elevates delisting risk and reinforces governance and control concerns, putting CELU at a clear disadvantage versus diversified healthcare and biotech benchmarks that generally maintain timely filings and stronger balance sheets. Execution of a credible compliance and recapitalization plan is mandatory but unlikely to re‑rate the stock near term. My verdict is strongly negative: avoid or trade tactically short, with resistance at $2.00 and downside support near $0.75 where prior consolidation occurred.
Quick Financial Overview
Celularity Inc. (CELU) is trading in a highly stressed backdrop. On the weekly tape, the stock jumped from around $0.86 into the low $2.00s before fading back toward the mid-$1.00s. That kind of spike-and-fade pattern tells traders this is a headline-driven, low-priced name where liquidity can vanish fast once the initial reaction cools. The intraday 5‑minute bar showing a move from above $2.10 down to the mid‑$1.00s in one candle confirms sharp intraday volatility and poor bid support.
Under the hood, the financial profile is heavy. Recent annual revenue is about $26.6M, but margins are deeply negative, with EBIT margin around -323% and profit margin near -346%. Gross margin is positive at 24.4%, yet operating costs and other expenses swamp the top line. Negative return on assets above -50% and a price‑to‑sales ratio near 1.5 show the market is still assigning real value to a business that is far from breakeven.
The balance sheet adds more risk. Celularity Inc. shows a current ratio of 0.2 and quick ratio of 0.1, which means short‑term obligations far exceed liquid assets. Stockholders’ equity is negative at roughly -$38.1M, reflecting large accumulated losses, while total liabilities sit around $145.4M on $107.3M of assets. Cash of about $6.2M against ongoing operating cash outflows of roughly -$5.1M in the last reported period suggests future funding needs if trends persist. For traders, all of this supports the idea that CELU trades as a speculative, news‑sensitive vehicle rather than a stable growth story.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.